Items where Author is "Croft, SL"
Up a level |
Number of items: 43.
2018
Van Bocxlaer, K;
Gaukel, E;
Hauser, D;
Park, SH;
Schock, S;
Yardley, V;
Randolph, R;
Plattner, JJ;
Merchant, T;
Croft, SL;
+2 more...
Jacobs, RT;
Wring, SA;
(2018)
Topical treatment for cutaneous leishmaniasis - dermato-pharmacokinetic led optimisation of benzoxaboroles.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.02419-17
Voak, AA;
Standing, JF;
Sepúlveda, N;
Harris, A;
Croft, SL;
Seifert, K;
(2018)
Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
The Journal of antimicrobial chemotherapy.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dky014
Wijnant, GJ;
Van Bocxlaer, K;
Fortes Francisco, A;
Yardley, V;
Harris, A;
Alavijeh, M;
Murdan, S;
Croft, SL;
(2018)
Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00631-18
Wijnant, GJ;
Van Bocxlaer, K;
Yardley, V;
Harris, A;
Alavijeh, M;
Silva-Pedrosa, R;
Antunes, S;
Mauricio, I;
Murdan, S;
Croft, SL;
(2018)
Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.
International journal for parasitology Drugs and drug resistance, 8 (2).
pp. 223-228.
ISSN 2211-3207
DOI: https://doi.org/10.1016/j.ijpddr.2018.04.001
2017
Baker, DA;
Stewart, LB;
Large, JM;
Bowyer, PW;
Ansell, KH;
Jiménez-Díaz, MB;
El Bakkouri, M;
Birchall, K;
Dechering, KJ;
Bouloc, NS;
+19 more...
Coombs, PJ;
Whalley, D;
Harding, DJ;
Smiljanic-Hurley, E;
Wheldon, MC;
Walker, EM;
Dessens, JT;
Lafuente, MJ;
Sanz, LM;
Gamo, FJ;
Ferrer, SB;
Hui, R;
Bousema, T;
Angulo-Barturén, I;
Merritt, AT;
Croft, SL;
Gutteridge, WE;
Kettleborough, CA;
Osborne, SA;
(2017)
A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.
Nature communications, 8 (1).
p. 430.
ISSN 2041-1723
DOI: https://doi.org/10.1038/s41467-017-00572-x
Basilico, N;
Parapini, S;
Sparatore, A;
Romeo, S;
Misiano, P;
Vivas, L;
Yardley, V;
Croft, SL;
Habluetzel, A;
Lucantoni, L;
+8 more...
Renia, L;
Russell, B;
Suwanarusk, R;
Nosten, F;
Dondio, G;
Bigogno, C;
Jabes, D;
Taramelli, D;
(2017)
In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial.
Molecules (Basel, Switzerland), 22 (12).
ISSN 1420-3049
DOI: https://doi.org/10.3390/molecules22122102
Burrell-Saward, H;
Harris, AJ;
de LaFlor, R;
Sallam, H;
Alavijeh, MS;
Ward, TH;
Croft, SL;
(2017)
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human african trypanosomiasis.
International journal of antimicrobial agents, 50 (2).
pp. 203-209.
ISSN 0924-8579
DOI: https://doi.org/10.1016/j.ijantimicag.2017.01.038
Croft, SL;
(2017)
Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.
Parasitology.
pp. 1-11.
ISSN 0031-1820
DOI: https://doi.org/10.1017/S0031182017001664
Voak, AA;
Harris, A;
Qaiser, Z;
Croft, SL;
Seifert, K;
(2017)
Treatment of experimental visceral leishmaniasis with single-dose liposomal amphotericin B - pharmacodynamics and biodistribution at different stages of disease.
Antimicrobial agents and chemotherapy, 61 (9).
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00497-17
Wijnant, GJ;
Van Bocxlaer, K;
Yardley, V;
Harris, A;
Murdan, S;
Croft, SL;
(2017)
AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.02009-17
Wijnant, GJ;
Van Bocxlaer, K;
Yardley, V;
Murdan, S;
Croft, S;
(2017)
Efficacy of a Paromomycin plus Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Antimicrobial agents and chemotherapy.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00358-17
2016
Cameron, MM;
Acosta-Serrano, A;
Bern, C;
Boelaert, M;
den Boer, M;
Burza, S;
Chapman, LA;
Chaskopoulou, A;
Coleman, M;
Courtenay, O;
+21 more...
Croft, S;
Das, P;
Dilger, E;
Foster, G;
Garlapati, R;
Haines, L;
Harris, A;
Hemingway, J;
Hollingsworth, TD;
Jervis, S;
Medley, G;
Miles, M;
Paine, M;
Picado, A;
Poché, R;
Ready, P;
Rogers, M;
Rowland, M;
Sundar, S;
de Vlas, SJ;
Weetman, D;
(2016)
Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India.
Parasites & vectors, 9 (1).
p. 25.
ISSN 1756-3305
DOI: https://doi.org/10.1186/s13071-016-1309-8
Croft, SL;
(2016)
Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration.
Genome Biol, 17 (1).
p. 46.
ISSN 1474-760X
DOI: https://doi.org/10.1186/s13059-016-0916-1
Daunes, S;
Yardley, V;
Croft, SL;
D'Silva, C;
(2016)
Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense.
Bioorganic & medicinal chemistry.
ISSN 0968-0896
DOI: https://doi.org/10.1016/j.bmc.2016.12.016
Hendrickx, S;
Guerin, PJ;
Caljon, G;
Croft, SL;
Maes, L;
(2016)
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Parasitology, 145 (4).
pp. 453-463.
ISSN 0031-1820
DOI: https://doi.org/10.1017/S0031182016002031
Tegazzini, D;
Díaz, R;
Aguilar, F;
Peña, I;
Presa, JL;
Yardley, V;
Martin, JJ;
Coteron, JM;
Croft, SL;
Cantizani, J;
(2016)
A replicative in vitro assay for drug discovery against Leishmania donovani.
Antimicrobial agents and chemotherapy, 60 (6).
pp. 3524-32.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.01781-15
Van Bocxlaer, K;
Yardley, V;
Murdan, S;
Croft, SL;
(2016)
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
The Journal of pharmacy and pharmacology, 68 (7).
pp. 862-72.
ISSN 0022-3573
DOI: https://doi.org/10.1111/jphp.12548
Van Bocxlaer, K;
Yardley, V;
Murdan, S;
Croft, SL;
(2016)
Drug permeation and barrier damage in Leishmania-infected mouse skin.
The Journal of antimicrobial chemotherapy, 71 (6).
pp. 1578-85.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dkw012
Full text not available from this repository.
Xu, J;
Bergquist, R;
Qian, YJ;
Wang, Q;
Yu, Q;
Peeling, R;
Croft, S;
Guo, JG;
Zhou, XN;
(2016)
China-Africa and China-Asia Collaboration on Schistosomiasis Control: A SWOT Analysis.
Adv Parasitol, 92.
pp. 435-66.
ISSN 2163-6079
DOI: https://doi.org/10.1016/bs.apar.2016.02.005
Full text not available from this repository.
2015
Croft, SL;
Ward, S;
(2015)
The Nobel Prize in Medicine 2015: Two drugs that changed global health.
Science translational medicine, 7 (316).
316ed14.
ISSN 1946-6234
DOI: https://doi.org/10.1126/scitranslmed.aad5868
Full text not available from this repository.
Kaur, H;
Seifert, K;
Hawkes, GE;
Coumbarides, GS;
Alvar, J;
Croft, SL;
(2015)
Chemical and Bioassay Techniques to Authenticate Quality of the Anti-Leishmanial Drug Miltefosine.
The American journal of tropical medicine and hygiene, 92 (6 Suppl).
pp. 31-8.
ISSN 0002-9637
DOI: https://doi.org/10.4269/ajtmh.14-0586
Riede, O;
Seifert, K;
Oswald, D;
Endmann, A;
Hock, C;
Winkler, A;
Salguero, FJ;
Schroff, M;
Croft, SL;
Juhls, C;
(2015)
Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.
Gene therapy, 22 (8).
pp. 628-35.
ISSN 0969-7128
DOI: https://doi.org/10.1038/gt.2015.35
Seifert, K;
Juhls, C;
Salguero, FJ;
Croft, SL;
(2015)
Sequential chemo-immunotherapy of experimental visceral leishmaniasis using single low dose liposomal amphotericin B and a novel DNA vaccine candidate.
Antimicrobial agents and chemotherapy, 59 (9).
pp. 5819-23.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.00273-15
Full text not available from this repository.
2014
Barrett, MP;
Croft, SL;
(2014)
Emerging paradigms in anti-infective drug design.
Parasitology, 141 (1).
pp. 1-7.
ISSN 0031-1820
DOI: https://doi.org/10.1017/S0031182013001224
Burrell-Saward, H;
Rodgers, J;
Bradley, B;
Croft, SL;
Ward, TH;
(2014)
A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis.
The Journal of antimicrobial chemotherapy, 70 (2).
pp. 510-7.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dku393
Das, S;
Freier, A;
Boussoffara, T;
Das, S;
Oswald, D;
Losch, FO;
Selka, M;
Sacerdoti-Sierra, N;
Schönian, G;
Wiesmüller, KH;
+10 more...
Seifert, K;
Schroff, M;
Juhls, C;
Jaffe, CL;
Roy, S;
Das, P;
Louzir, H;
Croft, SL;
Modabber, F;
Walden, P;
(2014)
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.
Science translational medicine, 6 (234).
234ra56.
ISSN 1946-6234
DOI: https://doi.org/10.1126/scitranslmed.3008222
Full text not available from this repository.
Ganguly, NK;
Croft, S;
Singh, L;
Sinha, S;
Balganesh, T;
(2014)
Biomedicine and biotechnology: public health impact.
BioMed research international, 2014.
p. 524785.
ISSN 2314-6133
DOI: https://doi.org/10.1155/2014/524785
Lamour, SD;
Veselkov, KA;
Posma, JM;
Giraud, E;
Rogers, ME;
Croft, S;
Marchesi, JR;
Holmes, E;
Seifert, K;
Saric, J;
(2014)
Metabolic, Immune, and Gut Microbial Signals Mount a Systems Response to Leishmania major Infection.
Journal of proteome research, 14 (1).
pp. 318-329.
ISSN 1535-3893
DOI: https://doi.org/10.1021/pr5008202
Full text not available from this repository.
Sanderson, L;
Yardley, V;
Croft, SL;
(2014)
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
The Journal of antimicrobial chemotherapy.
ISSN 0305-7453
DOI: https://doi.org/10.1093/jac/dku069
Full text not available from this repository.
2012
Mohamed-Ahmed, AH;
Brocchini, S;
Croft, SL;
(2012)
Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis.
Current opinion in infectious diseases, 25 (6).
pp. 695-702.
ISSN 0951-7375
DOI: https://doi.org/10.1097/QCO.0b013e328359eff2
Full text not available from this repository.
2011
Croft, SL;
Olliaro, P;
(2011)
Leishmaniasis chemotherapy-challenges and opportunities.
Clinical microbiology and infection, 17 (10).
pp. 1478-83.
ISSN 1198-743X
DOI: https://doi.org/10.1111/j.1469-0691.2011.03630.x
Full text not available from this repository.
2009
Luna, KP;
Hernandez, IP;
Rueda, CM;
Zorro, MM;
Croft, SL;
Escobar, P;
(2009)
In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole.
Biomedica, 29 (3).
pp. 448-455.
ISSN 0120-4157
http://researchonline.lshtm.ac.uk/id/eprint/4496
Full text not available from this repository.
2008
Fattorusso, C;
Campiani, G;
Kukreja, G;
Persico, M;
Butini, S;
Romano, MP;
Altarelli, M;
Rost, S;
Brindisi, M;
Savini, L;
+10 more...
Novellino, E;
Nacci, V;
Fattorusso, E;
Parapini, S;
Basilico, N;
Taramelli, D;
Yardley, V;
Croft, S;
Borriello, M;
Gemma, S;
(2008)
Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents.
Journal of medicinal chemistry, 51 (5).
pp. 1333-1343.
ISSN 0022-2623
DOI: https://doi.org/10.1021/jm7012375
Full text not available from this repository.
2007
Blackie, MAL;
Beagley, P;
Croft, SL;
Kendrick, H;
Moss, JR;
Chibale, K;
(2007)
Metallocene-based antimalarials: An exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum.
Bioorganic & medicinal chemistry, 15 (20).
pp. 6510-6516.
ISSN 0968-0896
DOI: https://doi.org/10.1016/j.bmc.2007.07.012
Full text not available from this repository.
Seifert, K;
Perez-Victoria, FJ;
Stettler, M;
Sánchez-Cañete, MP;
Castanys, S;
Gamarro, F;
Croft, SL;
(2007)
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
International journal of antimicrobial agents, 30 (3).
pp. 229-35.
ISSN 0924-8579
DOI: https://doi.org/10.1016/j.ijantimicag.2007.05.007
Full text not available from this repository.
2006
Laurent, T;
Rijal, S;
Yardley, V;
Croft, S;
De Doncker, S;
Decuypere, S;
Khanal, B;
Singh, R;
Schönian, G;
Kuhls, K;
+2 more...
Chappuis, F;
Dujardin, JC;
(2006)
Epidemiological dynamics of antimonial resistance in Leishmania donovani: Genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.
Infection, genetics and evolution, 7 (2).
pp. 206-12.
ISSN 1567-1348
DOI: https://doi.org/10.1016/j.meegid.2006.08.005
Full text not available from this repository.
Perez-Victoria, FJ;
Sanchez-Canete, MP;
Seifert, K;
Croft, SL;
Sundar, S;
Castanys, S;
Gamarro, F;
(2006)
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
Drug resistance updates, 9 (1-2).
pp. 26-39.
ISSN 1368-7646
DOI: https://doi.org/10.1016/j.drup.2006.04.001
Full text not available from this repository.
2005
Yardley, V;
Croft, SL;
DE Doncker, S;
Dujardin, JC;
Koirala, S;
Rijal, S;
Miranda, C;
Llanos-Cuentas, A;
Chappuis, F;
(2005)
THE SENSITIVITY OF CLINICAL ISOLATES OF LEISHMANIA FROM PERU AND NEPAL TO MILTEFOSINE.
The American journal of tropical medicine and hygiene, 73 (2).
pp. 272-5.
ISSN 0002-9637
http://researchonline.lshtm.ac.uk/id/eprint/13280
2004
Ghosh, S;
Chan, JMW;
Lea, CR;
Meints, GA;
Lewis, JC;
Tovian, ZS;
Flessner, RM;
Loftus, TC;
Bruchhaus, I;
Kendrick, H;
+5 more...
Croft, SL;
Kemp, RG;
Kobayashi, S;
Nozaki, T;
Oldfield, E;
(2004)
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Journal of medicinal chemistry, 47 (1).
pp. 175-187.
ISSN 0022-2623
DOI: https://doi.org/10.1021/jm030084x
Full text not available from this repository.
2003
Croft, SL;
Coombs, GH;
(2003)
Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs.
Trends in parasitology, 19 (11).
pp. 502-8.
ISSN 1471-4922
DOI: https://doi.org/10.1016/j.pt.2003.09.008
Full text not available from this repository.
Gokhale, NH;
Padhye, SB;
Croft, SL;
Kendrick, HD;
Davies, W;
Anson, CE;
Powell, AK;
(2003)
Transition metal complexes of buparvaquone as potent new antimalarial agents 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against Plasmodium falciparum.
Journal of inorganic biochemistry, 95 (4).
pp. 249-258.
ISSN 0162-0134
DOI: https://doi.org/10.1016/s0162-0134(03)00134-x
Full text not available from this repository.
Larabi, M;
Yardley, V;
Loiseau, PM;
Appel, M;
Legrand, P;
Gulik, A;
Bories, C;
Croft, SL;
Barratt, G;
(2003)
Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B.
Antimicrobial agents and chemotherapy, 47 (12).
pp. 3774-3779.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.47.12.3774-3779.2003
Full text not available from this repository.
Magaraci, F;
Jimenez, CJ;
Rodrigues, C;
Rodrigues, JCF;
Braga, MV;
Yardley, V;
de Luca-Fradley, K;
Croft, SL;
de Souza, W;
Ruiz-Perez, LM;
+3 more...
Urbina, J;
Pacanowska, DG;
Gilbert, IH;
(2003)
Azasterols as inhibitors of sterol 24-methyltransferase in leishmania species and Trypanosoma cruzi.
Journal of medicinal chemistry, 46 (22).
pp. 4714-4727.
ISSN 0022-2623
DOI: https://doi.org/10.1021/jm021114j
Full text not available from this repository.